A Phase 1 interventional study of MEDI-551 30 MG-IV and MEDI-551 60 MG-SC in Multiple Sclerosis, Relapsing Forms, sponsored by MedImmune LLC. Completed at 16 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-29.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 259 under way, 23 of them phase 3. Multiple Sclerosis · United States.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 404th largest by enrollment of the 879 interventional ones that give a count, is one of 41 that started in 2012, is one of 105 in phase 1, and was the 306th registered.
3,269 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 40–70
University of Texas at Austin · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,192 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 191 · Phase 3 142 · Phase 4 82
First in 1976; this study’s year is marked. 41 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 56 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 50 across the 879 interventional studies, 100 across the 302 observational. Of the 818 that completed or were terminated, 332 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
376 of 1,192 have an industry lead sponsor. The 10 most frequent:
This study is registered under MedImmune LLC, one of the names counted as AstraZeneca. Under that name alone:
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
AstraZeneca has 2 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
78 of the studies in Multiple Sclerosis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT06136728Phase 3MGH Institute of Health ProfessionsDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | 2027-05 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
Add all 78 to your calendar (.ics) → With an account.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of ascending intravenous (IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of multiple sclerosis (MS).
This is a Phase 1, multicenter, multinational, randomized, blinded, placebo-controlled, dose-escalation study to evaluate the safety and tolerability of IV and SC doses of MEDI-551 in adult subjects with relapsing forms of MS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
Drug: MEDI-551 30 MG-IV
Participants received SC injection of 60 mg MEDI-551 on Day 1.
Drug: MEDI-551 60 MG-SC
Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
Drug: MEDI-551 100 MG-IV
Participants received SC injection of 300 mg MEDI-551 on Day 1.
Drug: MEDI-551 300 MG-SC
Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
Drug: MEDI-551 600 MG-IV
Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1.
Drug: PLACEBO-IV-SC
Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
Participants received SC injection of 60 mg MEDI-551 on Day 1.
Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
Participants received SC injection of 300 mg MEDI-551 on Day 1.
Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A TEAE were the events between administration of study drug (Day 1) and Day 169 that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0
Time frame: From study drug administration (Day 1) through the end of treatment period (Day 169)
Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect in the offspring of a participant who received the study drug. The TESAEs were the events between administration of study drug (Day 1) and long term follow up period (up to 18 months after early discontinuation visit or 24-week treatment period) that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0
Time frame: From study drug administration (Day 1) through the long term follow up period (up to 18 months after early discontinuation visit or 24 week treatment period).
Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs
Any clinically significant change in laboratory evaluations were recorded as AEs. The following parameters were analyzed for laboratory evaluations: haematology, serum chemistry, and urinalysis. Number of participants with TEAEs related to laboratory evaluations were reported.
Time frame: From study drug administration (Day 1) through the end of treatment period (Day 169)
Number of Participants With Vital Sign Abnormalities Reported as TEAEs
Vital sign parameters included blood pressure, temperature, pulse rate, and respiratory rate. The number of participants with TEAEs related to vital signs in participants were reported.
Time frame: From study drug administration (Day 1) through the end of treatment period (Day 169)
Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-551
The time to reach the maximum observed serum concentration of MEDI-551.
Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Maximum Observed Serum Concentration (Cmax) of MEDI-551
The maximum observed serum concentration (Cmax) of MEDI-551.
Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551
The area under the concentration time curve from time 0 (dosing time) to the last measurable concentration (AUC 0-last) of MEDI-551.
Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551
The area under the concentration-time curve from dosing extrapolated to infinity (AUC 0-infinity) of MEDI-551.
Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Dose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-551
The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity post dose normalized by MEDI-551.
Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Clearance of MEDI-551
Systemic clearance (CL) for MEDI-551 IV cohorts and apparent clearance (CL/F) for MEDI-551 SC cohorts were calculated
Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Terminal Elimination Half-life (t1/2) of MEDI-551
The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI-551.
Time frame: Predose (Day 1) and Postdose (IV Cohorts only), Days 4 (SC Cohorts only), 8, 15 Predose and Postdose (IV Cohorts only), 29, 57, 85, 113, 141, and 169
Absolute Subcutaneous Bioavailability (F%) of MEDI-551
Bioavailability (F%) is the fraction of the study drug absorbed through non-intravenous administration compared with the corresponding intravenous administration of the same drug.
Time frame: Predose (Day 1) and Days 4, 8, 15, 29, 57, 85, 113, 141, and 169
Absolute CD20 B-cell Count at Baseline
Baseline absolute CD20 count is measured as the average between screening and predose on Day 1.
Time frame: Baseline (Days -28 to -1)
Time to 90 Percent (%) CD20 B-cell Depletion
Time in days of first observation where CD20 counts fall to or below 10 percent (%) of baseline.
Time frame: Baseline (Days -28 to -1) to long-term follow-up (LTFU) (Up to 18 months after EDV or 24 Week treatment period)
Duration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count
Time in days of last observation where CD20 counts remain at or below 10% of baseline. Participants whose samples are available were analyzed for this outcome measure.
Time frame: Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)
Maximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU
The maximum degree of depletion (intensity) measured during the course of the study for each participant by subtracting 100 from the lowest observed percent of baseline value.
Time frame: Baseline (Days -28 to -1) to LTFU (Up to 18 months after EDV or 24 Week treatment period)
Number of Participants Positive for Anti-Drug Antibodies to MEDI-551
A participant was considered anti-drug antibody positive across the study if they had a positive reading at any time point during the study.
Time frame: Days 1, 29, 85 and 169
This study was conducted from 30 Jul 2012 to 20 Jun 2016 in United States, Poland, Spain, and Ukraine.
| Milestone | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Started | 7 | 5 | 3 | 4 | 3 | 6 |
| Completed | 7 | 3 | 1 | 4 | 3 | 6 |
| Not completed | 0 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 1 | 0 | 0 | 0 |
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A TEAE were the events between administration of study drug (Day 1) and Day 169 that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0
| Participants | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 6 | 5 | 3 | 3 | 3 | 6 |
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect in the offspring of a participant who received the study drug. The TESAEs were the events between administration of study drug (Day 1) and long term follow up period (up to 18 months after early discontinuation visit or 24-week treatment period) that were absent before treatment or that worsened relative to pre-treatment state. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0
| Participants | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) | 1 | 1 | 0 | 0 | 1 | 1 |
Any clinically significant change in laboratory evaluations were recorded as AEs. The following parameters were analyzed for laboratory evaluations: haematology, serum chemistry, and urinalysis. Number of participants with TEAEs related to laboratory evaluations were reported.
| Participants | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Hematology- Anaemia | 1 | 0 | 0 | 0 | 0 | 0 |
| Hematology- White blood cell count decreased | 0 | 0 | 0 | 1 | 0 | 0 |
| Serum chemistry- Liver function test increased | 0 | 1 | 0 | 0 | 0 | 0 |
| Serum chemistry- Hyponatraemia | 0 | 0 | 0 | 0 | 0 | 1 |
Vital sign parameters included blood pressure, temperature, pulse rate, and respiratory rate. The number of participants with TEAEs related to vital signs in participants were reported.
| Participants | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Blood pressure increased | 1 | 0 | 1 | 0 | 0 | 2 |
| Blood pressure decreased | 0 | 0 | 1 | 0 | 0 | 0 |
| Tachycardia | 0 | 0 | 1 | 0 | 0 | 0 |
The time to reach the maximum observed serum concentration of MEDI-551.
| Day | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|
| Time to Reach Maximum Observed Serum Concentration (Tmax) of MEDI-551 | 0.14 (0.11 to 0.19) | 2.98 (2.87 to 6.97) | 0.07 (0.01 to 0.11) | 7.92 (7.82 to 8.02) | 0.12 (0.11 to 0.18) |
The maximum observed serum concentration (Cmax) of MEDI-551.
| microgram per milliliter (mcg/mL) | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of MEDI-551 | 17.9 ± 13.2 | 6.67 ± 2.88 | 43.1 ± 11.4 | 24.7 ± 9.37 | 248 ± 66.8 |
The area under the concentration time curve from time 0 (dosing time) to the last measurable concentration (AUC 0-last) of MEDI-551.
| microgram*day per milliliter(mcg*day/mL) | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC 0-last) of MEDI-551 | 436 ± NA | 197 ± 92.6 | 1140 ± 278 | 788 ± 455 | 6850 ± 1340 |
The area under the concentration-time curve from dosing extrapolated to infinity (AUC 0-infinity) of MEDI-551.
| mcg*day/mL | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity) of MEDI-551 | 440 ± NA | 201 ± 91.5 | 1150 ± 286 | 794 ± 453 | 6950 ± 1430 |
The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity post dose normalized by MEDI-551.
| mcg*day/mL/mg | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|
| Dose Normalized Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC 0-infinity/D) of MEDI-551 | 7.34 ± NA | 3.35 ± 1.52 | 5.75 ± 1.43 | 2.65 ± 1.51 | 5.79 ± 1.19 |
Systemic clearance (CL) for MEDI-551 IV cohorts and apparent clearance (CL/F) for MEDI-551 SC cohorts were calculated
| mL/day | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|
| Clearance of MEDI-551 | 139 ± NA | 351 ± 177 | 181 ± 44.5 | 457 ± 214 | 180 ± 41.5 |
The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI-551.
| Day | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|
| Terminal Elimination Half-life (t1/2) of MEDI-551 | 17.7 ± NA | 12.3 ± 1.71 | 17.7 ± 6.27 | 15.1 ± 4.31 | 18.7 ± 2.03 |
Bioavailability (F%) is the fraction of the study drug absorbed through non-intravenous administration compared with the corresponding intravenous administration of the same drug.
| Percentage of bioavailability | MEDI-551 60 Mg-SC | MEDI-551 300 Mg-SC |
|---|---|---|
| Absolute Subcutaneous Bioavailability (F%) of MEDI-551 | 58 | 46 |
Baseline absolute CD20 count is measured as the average between screening and predose on Day 1.
| cells/mcL | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Absolute CD20 B-cell Count at Baseline | 190 ± 99.1 | 173 ± 36.1 | 180 ± 108 | 183 ± 65.5 | 366 ± 257 | 201 ± 91.3 |
Time in days of first observation where CD20 counts fall to or below 10 percent (%) of baseline.
| Day | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Time to 90 Percent (%) CD20 B-cell Depletion | — | 15.0 ± 1.10 | 88.0 ± 50.3 | 25.0 ± 6.19 | 15.0 ± 4.04 | 14.5 ± 5.65 |
Time in days of last observation where CD20 counts remain at or below 10% of baseline. Participants whose samples are available were analyzed for this outcome measure.
| Day | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Duration of Suppression Greater Than or Equal to 90 % of CD20 B-cell Count | — | 149 ± 62.8 | 100 ± 28.3 | 180 ± 39.2 | 211 ± 17.3 | 254 ± 45.3 |
The maximum degree of depletion (intensity) measured during the course of the study for each participant by subtracting 100 from the lowest observed percent of baseline value.
| Percentage of cells | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Maximum Change From Baseline in Absolute CD20 of Peripheral Blood B-cell Count to LTFU | 25.0 ± 31.2 | 99.8 ± 0.0770 | 99.2 ± 0.787 | 99.7 ± 0.225 | 99.8 ± 0.182 | 99.8 ± 0.237 |
A participant was considered anti-drug antibody positive across the study if they had a positive reading at any time point during the study.
| Participants | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| Day 1 (Baseline) | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 29 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 85 | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 169 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over AEs were collected from the time of signature on informed consent through Day 169, SAEs were collected upto the long-term follow-up period (up to 18 months after early discontinuation visit or 24-week treatment period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PLACEBO-IV-SC | — | 1/7 (14.3%) | 5/7 (71.4%) |
| MEDI-551 60 Mg-SC | — | 0/3 (0%) | 3/3 (100%) |
| MEDI-551 100 Mg-IV | — | 0/4 (0%) | 3/4 (75%) |
| MEDI-551 300 Mg-SC | — | 1/3 (33.3%) | 2/3 (66.7%) |
| MEDI-551 30 Mg-IV | — | 1/5 (20%) | 4/5 (80%) |
| MEDI-551 600 Mg-IV | — | 1/6 (16.7%) | 6/6 (100%) |
| Event | PLACEBO-IV-SC | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 30 Mg-IV | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/7 | 0/3 | 0/4 | 1/3 | 0/5 | 0/6 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/7 | 0/3 | 0/4 | 0/3 | 1/5 | 0/6 |
| Urinary tract infectionInfections and infestations | 0/7 | 0/3 | 0/4 | 0/3 | 0/5 | 1/6 |
| Multiple sclerosis relapseNervous system disorders | 1/7 | 0/3 | 0/4 | 0/3 | 0/5 | 0/6 |
| Event | PLACEBO-IV-SC | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 30 Mg-IV | MEDI-551 600 Mg-IV |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/7 | 0/3 | 2/4 | 1/3 | 1/5 | 1/6 |
| Oral herpesInfections and infestations | 1/7 | 0/3 | 2/4 | 0/3 | 0/5 | 0/6 |
| Upper respiratory tract infectionInfections and infestations | 0/7 | 1/3 | 2/4 | 0/3 | 1/5 | 0/6 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/7 | 0/3 | 1/4 | 0/3 | 2/5 | 3/6 |
| AstheniaGeneral disorders | 0/7 | 0/3 | 1/4 | 1/3 | 0/5 | 0/6 |
| PyrexiaGeneral disorders | 0/7 | 1/3 | 1/4 | 0/3 | 0/5 | 0/6 |
| Urinary tract infectionInfections and infestations | 0/7 | 1/3 | 0/4 | 1/3 | 0/5 | 1/6 |
| Blood pressure increasedInvestigations | 1/7 | 1/3 | 0/4 | 0/3 | 0/5 | 2/6 |
| Back painMusculoskeletal and connective tissue disorders | 1/7 | 0/3 | 1/4 | 1/3 | 0/5 | 0/6 |
| HeadacheNervous system disorders | 1/7 | 0/3 | 0/4 | 1/3 | 0/5 | 1/6 |
Safety Population is defined as all participants who received any amount of study drug. One participant in the 30 mg IV dose cohort received an incorrect dose of study drug due to kits not administered according to the IVRS; the participant received MEDI-551 100 mg IV instead of 30 mg on Day 1.
| Age, Continuous(Years) | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV | Total |
|---|---|---|---|---|---|---|---|
| Mean | 43.0 ± 15.9 | 42.4 ± 7.8 | 46.7 ± 16.3 | 46.5 ± 13.8 | 56.0 ± 6.1 | 44.2 ± 10.1 | 45.4 ± 12.0 |
| Sex: Female, Male(Participants) | PLACEBO-IV-SC | MEDI-551 30 Mg-IV | MEDI-551 60 Mg-SC | MEDI-551 100 Mg-IV | MEDI-551 300 Mg-SC | MEDI-551 600 Mg-IV | Total |
|---|---|---|---|---|---|---|---|
| Female | 6 | 3 | 2 | 3 | 2 | 3 | 19 |
| Male | 1 | 2 | 1 | 1 | 1 | 3 | 9 |
Ran from Apr 2012 to primary completion in Jan 2015, 32 months.
Results were first posted in Oct 2018, 3 years 9 months after primary completion.
Of 39 industry-sponsored phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 32. This study's 32 months is above that.
Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inebilizumab